Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.57 |
| ▸ | CDC25B | P30305 | 8/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.57 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.57 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.57 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.52 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.52 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232797 | 1.00 | NT5E (0.58) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL6233124 | 1.00 | NT5E (0.58) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL6357791 | 1.00 | NT5E (0.58) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8723272 | 1.00 | NT5E (0.58) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL5556044 | 1.00 | NT5E (0.58) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL6233127 | 1.00 | NT5E (0.58) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL6229377 | 1.00 | NT5E (0.58) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL6235085 | 0.99 | NT5E (0.59) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL6235082 | 0.99 | NT5E (0.59) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL29410628 | 0.91 | PTPN1 (0.56) | NT5EPTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908989-B2 | Process for the production of perbenzylated 1-O-glycosides | SCHERING AG (DE) | 2005-06-21 | — | — | US | disclosed |
| EP-1397376-B1 | METHOD FOR PRODUCING PERBENZYLATED 1-O-GLYCOSIDES | SCHERING AG (DE) | 2005-05-04 | — | — | EP | disclosed |
| EP-1397376-A1 | METHOD FOR PRODUCING PERBENZYLATED 1-O-GLYCOSIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1261614-B1 | METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES | SCHERING AG (DE) | 2004-01-07 | — | — | EP | disclosed |
| US-6545135-B2 | Alkylation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-08 | — | — | US | disclosed |
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002102816-A1 | METHOD FOR PRODUCING PERBENZYLATED 1-O-GLYCOSIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-27 | — | — | WO | disclosed |
| EP-1261614-A2 | METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | SCHERING AKTIENGESELLSCHAFT | 2002-01-03 | — | — | US | disclosed |
| WO-2001068659-A2 | METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | MAN1B1, STT3B, OSTC | NT5E 4254/4885PTPN1 1928/4885CDC25B 1637/4885 |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | STT3B, MAN1B1, OSTC | NT5E 4064/4885PTPN1 2526/4885CDC25B 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.